"Founded in 1983, Eyesight Ophthalmic Services is Southern New Hampshire’s leading provider of eye care for both adults and children. Eyesight’s offices may be visited at one of three convenient locations in Portsmouth, Exeter, and Somersworth New Hampshire."

During the past decade, Eyesight Ophthalmic Services, PA conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 3 clinical trials were completed, i.e. on average, 150% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Eyesight Ophthalmic Services, PA" #1 sponsor was "Jaeb Center for Health Research" with 5 trials, followed by "Alimera Sciences" with 1 trials sponsored, "Allergan" with 1 trials sponsored, "Bausch & Lomb Incorporated" with 1 trials sponsored and "Quark Pharmaceuticals" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Eyesight Ophthalmic Services, PA" #1 collaborator was "National Eye Institute (NEI)" with 5 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator, "Allergan" with 2 trials as a collaborator, "Regeneron Pharmaceuticals" with 2 trials as a collaborator and "National Institutes of Health (NIH)" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Eyesight Ophthalmic Services, PA" are "Diabetic Macular Edema" (6 trials), "Diabetic Retinopathy" (2 trials), "Choroidal Neovascularization" (1 trials), "Diabetic Macular Edema (DME)" (1 trials) and "Eye Infections" (1 trials). Many other conditions were trialed in "Eyesight Ophthalmic Services, PA" in a lesser frequency.

Most popular intervention types in "Eyesight Ophthalmic Services, PA" are "Drug" (9 trials), "Procedure" (2 trials), "Behavioral" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "0.3 mg intravitreal ranibizumab" (1 trials), "1.25 mg intravitreal bevacizumab" (1 trials), "2.0 mg intravitreal aflibercept" (1 trials), "Abicipar pegol" (1 trials) and "Deferred aflibercept" (1 trials). Other intervention names were less common.

The vast majority of trials in "Eyesight Ophthalmic Services, PA" are 9 trials for "All" genders.

Currently, there are NaN active trials in "Eyesight Ophthalmic Services, PA". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Eyesight Ophthalmic Services, PA, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Eyesight Ophthalmic Services, PA, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".